KCNN4 and triple-negative breast carcinoma: Testing of known or novel KCa3.1 inhibitors, possibly in combination with classical DNA-targeting drugs, might well unveil an essential role for KCa3.1 expression in breast cancer growth and survival, and yield a venue of treatment yet unavailable for patients suffering from aggressive, basal-like or triple-negative breast cancer.